Analyst Viewpoint
Increase in prevalence of cancer is a prominent factor contributing to the oncology nutrition market size. Cancer is one of the most common causes of death globally, with a majority of patients suffering some form of malnourishment and nutrient deficiency during the treatment process.
Improvement in awareness of the role of nutrition in cancer treatment due to concentrated efforts by advocacy groups, government, and healthcare institutions is augmenting the oncology nutrition market expansion.
Dietary considerations in oncology patient care must include tumor-fighting nutrients, calories, fats, and essential vitamins and minerals.
Prominent players operating in the oncology nutrition industry are investing substantially in developing tumor-specific nutritional therapies and oncological nutrient strategies to cater to a growing demand for innovative healthcare solutions.
Oncology nutrition refers to specific dietary plans and interventions designed to address the needs of cancer patients as they suffer from appetite loss, nutrient deficiencies, and weight changes.
Oncological dietary support improves the functioning of bodily resources, tolerance of cancer treatment, and overall quality of the patient’s life.
Cancer-related malnutrition is common in the majority of cancer patients as the exhaustion and bodily changes caused by the treatment lead to weight loss and nutrient deficiencies. Integration of nutritional screening and assessment techniques in cancer care methodologies is set to advance the oncology nutrition industry.
Recent oncology nutrition market trends showcase research around the role of micronutrients in supporting oncology therapies along with the integration of digital nutritional platforms that offer personalized diets for cancer patients and remote support.
Cancer is a globally prevalent disease and a leading cause of death worldwide. A drastic surge in the global old age population, an unhealthy modern lifestyle across age groups, and certain genetic predispositions are primary contributors to the surge in number of cancer cases.
According to the World Health Organization (WHO), various types of cancers together account for every sixth death around the world. By the year 2030, the international organization states that there might be an estimated 21 million new cases of cancer annually.
Heightened expenditure on cancer care is expected to spur the oncology nutrition market growth in the near future. As per the National Health Services (NHS), in 2022, in the U.K., cancer care takes about 5% of the total national healthcare budget which amounts to nearly GBP 4.5 Bn annually.
The European Union’s Europe Beating Cancer Plan has overall funding of EUR 4 Bn with an additional fund transfer of EUR 1.2 Bn from EU4Health.
As per the National Cancer Institute, 30% to 85% of cancer patients experience malnourishment during their treatment process. The report by the institute also states that mortality in cancer patients due to malnourishment is only 10% to 20%.
A good diet and nutrition plan for cancer patients assists in mitigating the side effects of treatment, enhancing bodily functions, boosting immunity, and improving overall quality of life.
A well-balanced diet for a cancer patient differs from individual to individual and on cancer type. The consumption of adequate calories, minerals, vitamins, and fats aids in pain relief, enhances the chances of survival, and maintains a positive outlook during rounds of exhausting therapy.
Educational initiatives, advocacy efforts, supportive government policies, and healthcare workers' training programs are the prime contributors that lead to the increase in awareness of the role of nutrition in cancer treatment, thereby, propelling the oncology nutrition market value.
North America held the largest oncology nutrition market share in 2022. Presence of a well-developed healthcare sector, enhanced awareness about advanced cancer care solutions, and R&D of new therapeutics are augmenting the market dynamics of the region.
According to a report by the Canadian Cancer Society, in 2023, Canada had 239,100 new cancer cases and 86,700 cancer-related deaths. In the past 25 years, 1 out of 24 people in Canada have been diagnosed with at least one type of cancer.
As per the latest oncology nutrition market analysis, the industry in Europe is projected to grow at a steady pace from 2023 to 2031. Focus on personalized medicine and cancer care along with supportive policies and guidelines implemented by the government are propelling the oncology nutrition industry statistics in the region.
The European Commission states that cancer care is a substantial burden to the European Union’s healthcare budget and leads to an expenditure of over EUR 100 Bn per year.
Prominent manufacturers in the market are investing significantly in the development of cancer-adapted dietary plans and nutritional oncology solutions in an attempt to offer patients an improved standard of living and assist healthcare workers in offering optimal care.
Danone S.A., Pfizer Inc., B. Braun Melsungen AG, Fresenius Kabi AG, Grifols S.A., Baxter International, Inc., Nestle S.A., Abbott Laboratories, AbbVie, Inc., and Sichuan Kelun Pharmaceutical Co., Ltd. are key companies operating in this market.
These companies have been profiled in the oncology nutrition market report based on various parameters such as business strategies, product portfolio, company overview, financial overview, and business segments.
| Attribute | Detail |
|---|---|
| Market Value in 2022 (Base Year) | US$ 2.1 Bn |
| Market Forecast Value in 2031 | US$ 3.6 Bn |
| Growth Rate (CAGR) | 6.2% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | Qualitative analysis includes drivers, restraints, opportunities, key trends, key market indicators, Porter’s Five Forces analysis, value chain analysis, and SWOT analysis. Furthermore, at the regional level, the qualitative analysis includes key trends, price trends, and key supplier analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon Request |
| Pricing | Available upon Request |
It was valued at US$ 2.1 Bn in 2022
It is projected to grow at a CAGR of 6.2% from 2023 to 2031
Rise in prevalence of cancer and increase in awareness of role of nutrition in cancer treatment
The outpatient nutrition segment accounted for the largest share in 2022
North America dominated the global landscape in 2022
Danone S.A., Pfizer Inc., B. Braun Melsungen AG, Fresenius Kabi AG, Grifols S.A., Baxter International, Inc., Nestle S.A., Abbott Laboratories, AbbVie, Inc., and Sichuan Kelun Pharmaceutical Co., Ltd.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Oncology Nutrition Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Oncology Nutrition Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Oncology Nutrition Market Analysis and Forecast, by Cancer Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Cancer Type, 2017–2031
6.3.1. Head and Neck Cancer
6.3.2. Colorectal Cancer
6.3.3. Hematology Cancer
6.3.4. Prostate Cancer
6.3.5. Breast Cancer
6.3.6. Gastrointestinal Cancer
6.3.7. Lung Cancer
6.3.8. Pancreatic Cancer
6.3.9. Others
6.4. Market Attractiveness, by Cancer Type
7. Global Oncology Nutrition Market Analysis and Forecast, by Nutrition
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Nutrition, 2017–2031
7.3.1. Enteral Nutrition
7.3.2. Parenteral Nutrition
7.4. Market Attractiveness, by Nutrition
8. Global Oncology Nutrition Market Analysis and Forecast, by Formula
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Formula, 2017–2031
8.3.1. Standard Formula
8.3.2. Elemental Formula
8.3.3. Specialized Formula
8.4. Market Attractiveness, by Formula
9. Global Oncology Nutrition Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Distribution Channel, 2017–2031
9.3.1. Inpatient Nutrition
9.3.2. Outpatient Nutrition
9.4. Market Attractiveness, by Distribution Channel
10. Global Oncology Nutrition Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017–2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America Oncology Nutrition Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Cancer Type, 2017–2031
11.2.1. Head and Neck Cancer
11.2.2. Colorectal Cancer
11.2.3. Hematology Cancer
11.2.4. Prostate Cancer
11.2.5. Breast Cancer
11.2.6. Gastrointestinal Cancer
11.2.7. Lung Cancer
11.2.8. Pancreatic Cancer
11.2.9. Others
11.3. Market Attractiveness, by Cancer Type
11.4. Market Value Forecast, by Nutrition, 2017–2031
11.4.1. Enteral Nutrition
11.4.2. Parenteral Nutrition
11.5. Market Attractiveness, by Nutrition
11.6. Market Value Forecast, by Formula, 2017–2031
11.6.1. Standard Formula
11.6.2. Elemental Formula
11.6.3. Specialized Formula
11.7. Market Attractiveness, by Formula
11.8. Market Value Forecast, by Distribution Channel
11.8.1. Inpatient Nutrition
11.8.2. Outpatient Nutrition
11.9. Market Attractiveness, by Distribution Channel
11.10. Market Value Forecast, by Country/Sub-region, 2017–2031
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Cancer Type
11.11.2. By Nutrition
11.11.3. By Formula
11.11.4. By Distribution Channel
11.11.5. By Country
12. Europe Oncology Nutrition Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Cancer Type, 2017–2031
12.2.1. Head and Neck Cancer
12.2.2. Colorectal Cancer
12.2.3. Hematology Cancer
12.2.4. Prostate Cancer
12.2.5. Breast Cancer
12.2.6. Gastrointestinal Cancer
12.2.7. Lung Cancer
12.2.8. Pancreatic Cancer
12.2.9. Others
12.3. Market Attractiveness, by Cancer Type
12.4. Market Value Forecast, by Nutrition, 2017–2031
12.4.1. Enteral Nutrition
12.4.2. Parenteral Nutrition
12.5. Market Attractiveness, by Nutrition
12.6. Market Value Forecast, by Formula, 2017–2031
12.6.1. Standard Formula
12.6.2. Elemental Formula
12.6.3. Specialized Formula
12.7. Market Attractiveness, by Formula
12.8. Market Value Forecast, by Distribution Channel, 2017–2031
12.8.1. Inpatient Nutrition
12.8.2. Outpatient Nutrition
12.9. Market Attractiveness, by Distribution Channel
12.10. Market Value Forecast, by Country/Sub-region, 2017–2031
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Cancer Type
12.11.2. By Nutrition
12.11.3. By Formula
12.11.4. By Distribution Channel
12.11.5. By Country/Sub-region
13. Asia Pacific Oncology Nutrition Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Cancer Type, 2017–2031
13.2.1. Head and Neck Cancer
13.2.2. Colorectal Cancer
13.2.3. Hematology Cancer
13.2.4. Prostate Cancer
13.2.5. Breast Cancer
13.2.6. Gastrointestinal Cancer
13.2.7. Lung Cancer
13.2.8. Pancreatic Cancer
13.2.9. Others
13.3. Market Attractiveness, by Cancer Type
13.4. Market Value Forecast, by Nutrition, 2017–2031
13.4.1. Enteral Nutrition
13.4.2. Parenteral Nutrition
13.5. Market Attractiveness, by Nutrition
13.6. Market Value Forecast, by Formula, 2017–2031
13.6.1. Standard Formula
13.6.2. Elemental Formula
13.6.3. Specialized Formula
13.7. Market Attractiveness, by Formula
13.8. Market Value Forecast, by Distribution Channel, 2017–2031
13.8.1. Inpatient Nutrition
13.8.2. Outpatient Nutrition
13.9. Market Attractiveness, by Distribution Channel
13.10. Market Value Forecast, by Country/Sub-region, 2017–2031
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Cancer Type
13.11.2. By Nutrition
13.11.3. By Formula
13.11.4. By Distribution Channel
13.11.5. By Country/Sub-region
14. Latin America Oncology Nutrition Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Cancer Type, 2017–2031
14.2.1. Head and Neck Cancer
14.2.2. Colorectal Cancer
14.2.3. Hematology Cancer
14.2.4. Prostate Cancer
14.2.5. Breast Cancer
14.2.6. Gastrointestinal Cancer
14.2.7. Lung Cancer
14.2.8. Pancreatic Cancer
14.2.9. Others
14.3. Market Attractiveness, by Cancer Type
14.4. Market Value Forecast, by Nutrition, 2017–2031
14.4.1. Enteral Nutrition
14.4.2. Parenteral Nutrition
14.5. Market Attractiveness, by Nutrition
14.6. Market Value Forecast, by Formula, 2017–2031
14.6.1. Standard Formula
14.6.2. Elemental Formula
14.6.3. Specialized Formula
14.7. Market Attractiveness, by Formula
14.8. Market Value Forecast, by Distribution Channel, 2017–2031
14.8.1. Inpatient Nutrition
14.8.2. Outpatient Nutrition
14.9. Market Attractiveness, by Distribution Channel
14.10. Market Value Forecast, by Country/Sub-region, 2017–2031
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Cancer Type
14.11.2. By Nutrition
14.11.3. By Formula
14.11.4. By Distribution Channel
14.11.5. By Country/Sub-region
15. Middle East & Africa Oncology Nutrition Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Cancer Type, 2017–2031
15.2.1. Head and Neck Cancer
15.2.2. Colorectal Cancer
15.2.3. Hematology Cancer
15.2.4. Prostate Cancer
15.2.5. Breast Cancer
15.2.6. Gastrointestinal Cancer
15.2.7. Lung Cancer
15.2.8. Pancreatic Cancer
15.2.9. Others
15.3. Market Attractiveness, by Cancer Type
15.4. Market Value Forecast, by Nutrition, 2017–2031
15.4.1. Enteral Nutrition
15.4.2. Parenteral Nutrition
15.5. Market Attractiveness, by Nutrition
15.6. Market Value Forecast, by Formula, 2017–2031
15.6.1. Standard Formula
15.6.2. Elemental Formula
15.6.3. Specialized Formula
15.7. Market Attractiveness, by Formula
15.8. Market Value Forecast, by Distribution Channel, 2017–2031
15.8.1. Inpatient Nutrition
15.8.2. Outpatient Nutrition
15.9. Market Attractiveness, by Distribution Channel
15.10. Market Value Forecast, by Country/Sub-region, 2017–2031
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Cancer Type
15.11.2. By Nutrition
15.11.3. By Formula
15.11.4. By Distribution Channel
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Danone S.A.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Pfizer Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. B. Braun Melsungen AG
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Fresenius Kabi AG
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Grifols S.A.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. Baxter International, Inc.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Nestle S.A.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Abbott Laboratories
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. AbbVie, Inc.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview
16.3.10. Sichuan Kelun Pharmaceutical Co., Ltd.
16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.10.2. Product Portfolio
16.3.10.3. Financial Overview
16.3.10.4. SWOT Analysis
16.3.10.5. Strategic Overview
List of Tables
Table 01: Global Oncology Nutrition Market Size (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 02: Global Oncology Nutrition Market Size (US$ Mn) Forecast, by Nutrition, 2017–2031
Table 03: Global Oncology Nutrition Market Size (US$ Mn) Forecast, by Formula, 2017–2031
Table 04: Global Oncology Nutrition Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 05: Global Oncology Nutrition Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 06: North America Oncology Nutrition Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 07: North America Oncology Nutrition Market Size (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 08: North America Oncology Nutrition Market Size (US$ Mn) Forecast, by Nutrition, 2017–2031
Table 09: North America Oncology Nutrition Market Size (US$ Mn) Forecast, by Formula, 2017–2031
Table 10: North America Oncology Nutrition Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 11: Europe Oncology Nutrition Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 12: Europe Oncology Nutrition Market Size (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 13: Europe Oncology Nutrition Market Size (US$ Mn) Forecast, by Nutrition, 2017–2031
Table 14: Europe Oncology Nutrition Market Size (US$ Mn) Forecast, by Formula, 2017–2031
Table 15: Europe Oncology Nutrition Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 16: Asia Pacific Oncology Nutrition Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Asia Pacific Oncology Nutrition Market Size (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 18: Asia Pacific Oncology Nutrition Market Size (US$ Mn) Forecast, by Nutrition, 2017–2031
Table 19: Asia Pacific Oncology Nutrition Market Size (US$ Mn) Forecast, by Formula, 2017–2031
Table 20: Asia Pacific Oncology Nutrition Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Latin America Oncology Nutrition Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Latin America Oncology Nutrition Market Size (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 23: Latin America Oncology Nutrition Market Size (US$ Mn) Forecast, by Nutrition, 2017–2031
Table 24: Latin America Oncology Nutrition Market Size (US$ Mn) Forecast, by Formula, 2017–2031
Table 25: Latin America Oncology Nutrition Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 26: Middle East & Africa Oncology Nutrition Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 27: Middle East & Africa Oncology Nutrition Market Size (US$ Mn) Forecast, by Cancer Type, 2017–2031
Table 28: Middle East & Africa Oncology Nutrition Market Size (US$ Mn) Forecast, by Nutrition, 2017–2031
Table 29: Middle East & Africa Oncology Nutrition Market Size (US$ Mn) Forecast, by Formula, 2017–2031
Table 30: Middle East & Africa Oncology Nutrition Market Size (US$ Mn) Forecast, by Distribution Channel, 2017–2031
List of Figures
Figure 01: Global Oncology Nutrition Market Size (US$ Mn) and Distribution (%), by Region, 2022–2031
Figure 02: Global Oncology Nutrition Market Revenue (US$ Mn), by Cancer Type, 2022
Figure 03: Global Oncology Nutrition Market Value Share, by Cancer Type, 2022
Figure 04: Global Oncology Nutrition Market Revenue (US$ Mn), by Nutrition, 2022
Figure 05: Global Oncology Nutrition Market Value Share, by Nutrition, 2022
Figure 06: Global Oncology Nutrition Market Revenue (US$ Mn), by Formula, 2022
Figure 07: Global Oncology Nutrition Market Value Share, by Formula, 2022
Figure 08: Global Oncology Nutrition Market Value Share, by Distribution Channel, 2022
Figure 09: Global Oncology Nutrition Market Value Share, by Distribution Channel, 2022
Figure 10: Global Oncology Nutrition Market Value Share, by Region, 2022
Figure 11: Global Oncology Nutrition Market Value (US$ Mn) Forecast, 2017–2031
Figure 12: Global Oncology Nutrition Market Value Share Analysis, by Cancer Type, 2022–2031
Figure 13: Global Oncology Nutrition Market Attractiveness Analysis, by Cancer Type, 2023–2031
Figure 14: Global Oncology Nutrition Market Value Share Analysis, by Nutrition, 2022–2031
Figure 15: Global Oncology Nutrition Market Attractiveness Analysis, by Nutrition, 2023–2031
Figure 16: Global Oncology Nutrition Market Value Share Analysis, by Formula, 2022–2031
Figure 17: Global Oncology Nutrition Market Attractiveness Analysis, by Formula, 2023–2031
Figure 18: Global Oncology Nutrition Market Revenue (US$ Mn), by Distribution Channel, 2022
Figure 19: Global Oncology Nutrition Market Value Share, by Distribution Channel, 2022
Figure 20: Global Oncology Nutrition Market Value Share Analysis, by Region, 2022–2031
Figure 21: Global Oncology Nutrition Market Attractiveness Analysis, by Region, 2023–2031
Figure 22: North America Oncology Nutrition Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 23: North America Oncology Nutrition Market Attractiveness Analysis, by Country, 2023–2031
Figure 24: North America Oncology Nutrition Market Value Share Analysis, by Country, 2022–2031
Figure 25: North America Oncology Nutrition Market Value Share Analysis, by Cancer Type, 2022–2031
Figure 26: North America Oncology Nutrition Market Value Share Analysis, by Nutrition, 2022–2031
Figure 27: North America Oncology Nutrition Market Value Share Analysis, by Formula, 2022–2031
Figure 28: North America Oncology Nutrition Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 29: North America Oncology Nutrition Market Attractiveness Analysis, by Cancer Type, 2017–2031
Figure 30: North America Oncology Nutrition Market Attractiveness Analysis, by Nutrition, 2023–2031
Figure 31: North America Oncology Nutrition Market Attractiveness Analysis, by Formula, 2023–2031
Figure 32: North America Oncology Nutrition Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 33: Europe Oncology Nutrition Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 34: Europe Oncology Nutrition Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 35: Europe Oncology Nutrition Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 36: Europe Oncology Nutrition Market Value Share Analysis, by Cancer Type, 2022–2031
Figure 37: Europe Oncology Nutrition Market Value Share Analysis, by Nutrition, 2022–2031
Figure 38: Europe Oncology Nutrition Market Value Share Analysis, by Formula, 2022–2031
Figure 39: Europe Oncology Nutrition Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 40: Europe Oncology Nutrition Market Attractiveness Analysis, by Cancer Type, 2023–2031
Figure 41: Europe Oncology Nutrition Market Attractiveness Analysis, by Nutrition, 2023–2031
Figure 42: Europe Oncology Nutrition Market Attractiveness Analysis, by Formula, 2023–2031
Figure 43: Europe Oncology Nutrition Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 44: Asia Pacific Oncology Nutrition Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 45: Asia Pacific Oncology Nutrition Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 46: Asia Pacific Oncology Nutrition Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 47: Asia Pacific Oncology Nutrition Market Value Share Analysis, by Cancer Type, 2022–2031
Figure 48: Asia Pacific Oncology Nutrition Market Value Share Analysis, by Nutrition, 2022–2031
Figure 49: Asia Pacific Oncology Nutrition Market Value Share Analysis, by Formula, 2022–2031
Figure 50: Asia Pacific Oncology Nutrition Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 51: Asia Pacific Oncology Nutrition Market Attractiveness Analysis, by Cancer Type, 2023–2031
Figure 52: Asia Pacific Oncology Nutrition Market Attractiveness Analysis, by Nutrition, 2023–2031
Figure 53: Asia Pacific Oncology Nutrition Market Attractiveness Analysis, by Formula, 2023–2031
Figure 54: Asia Pacific Oncology Nutrition Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 55: Latin America Oncology Nutrition Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 56: Latin America Oncology Nutrition Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 57: Latin America Oncology Nutrition Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 58: Latin America Oncology Nutrition Market Value Share Analysis, by Cancer Type, 2022–2031
Figure 59: Latin America Oncology Nutrition Market Value Share Analysis, by Nutrition, 2022–2031
Figure 60: Latin America Oncology Nutrition Market Value Share Analysis, by Formula, 2022–2031
Figure 61: Latin America Oncology Nutrition Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 62: Latin America Oncology Nutrition Market Attractiveness Analysis, by Cancer Type, 2023–2031
Figure 63: Latin America Oncology Nutrition Market Attractiveness Analysis, by Nutrition, 2023–2031
Figure 64: Latin America Oncology Nutrition Market Attractiveness Analysis, by Formula, 2023–2031
Figure 65: Latin America Oncology Nutrition Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Figure 66: Middle East & Africa Oncology Nutrition Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 67: Middle East & Africa Oncology Nutrition Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 68: Middle East & Africa Oncology Nutrition Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 69: Middle East & Africa Oncology Nutrition Market Value Share Analysis, by Cancer Type, 2022–2031
Figure 70: Middle East & Africa Oncology Nutrition Market Value Share Analysis, by Nutrition, 2022–2031
Figure 71: Middle East & Africa Oncology Nutrition Market Value Share Analysis, by Formula, 2022–2031
Figure 72: Middle East & Africa Oncology Nutrition Market Value Share Analysis, by Distribution Channel, 2022–2031
Figure 73: Middle East & Africa Oncology Nutrition Market Attractiveness Analysis, by Cancer Type, 2023–2031
Figure 74: Middle East & Africa Oncology Nutrition Market Attractiveness Analysis, by Nutrition, 2023–2031
Figure 75: Middle East & Africa Oncology Nutrition Market Attractiveness Analysis, by Formula, 2023–2031
Figure 76: Middle East & Africa Oncology Nutrition Market Attractiveness Analysis, by Distribution Channel, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Oncology Nutrition Market
*86 figures and 60 tables includes